Translational research in regenerative stem cell therapies for retinal degenerative diseases: from the swine animal model of retinal atrophy to clinical trials in human patients with age-related macular degeneration, retinitis pigmentosa and Stargardt’s disease 26/03/2013
To date, gene therapy or growth factor supplement strategies cannot regenerate retinal pigment epithelial (RPE) cells loss in degenerative retinal diseases. Cell therapy replacement strategies such the use of fetal tissue or embryonic stem cells (ESCs), are still subject to ethical concerns and the tumorigenic-associated responses linked to the use of fetal material. The main goal of this project is to identify the best method of differentiation from patient cells towards functional RPE and PR cells and to implant them in an animal model of geographic atrophy of the retina. The development of such technologies will allow the initiation of a phase I clinical trial in a-AMD, retinitis pigmentosa and Stargardt’s disease patients.
Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal